Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database

Mosmi Surati, Matthew R. Robinson, Suvobroto Nandi, Leonardo Faoro, Carley Demchuk, Cleo E. Rolle, Rajani Kanteti, Benjamin D. Ferguson, Rifat Hasina, Tara C. Gangadhar, April K.s. Salama, Qudsia Arif, Colin Kirchner, Eneida A. Mendonça, Nicholas Campbell, Suwicha Limvorasak, Victoria Villaflor, Thomas A. Hensing, Thomas Krausz, Everett E. Vokes, Aliya N. Husain, Mark K. Ferguson, Theodore Karrison, Ravi SalgiaJournal of Clinical Bioinformatics 2011 · DOI

Abstract

Though the database project is still under development, the application of such a database has the potential to enhance our understanding of cancer biology and will help researchers to identify targets to modify the course of thoracic malignancies.

Introduction

In oncology research, a persistent "data silo" problem often hinders progress. Clinical records, such as patient history and survival data, are frequently disconnected from basic science data like genomic mutations and protein expression. This fragmentation makes it difficult to determine if a specific molecular alteration significantly impacts a patient's prognosis or therapeutic response.

To address this, researchers at the University of Chicago developed the Thoracic Oncology Program Database Project (TOPDP). This relational database bridges the gap between clinical and molecular data, integrating information from over 1,300 lung cancer patients. By using non-small cell lung cancer (NSCLC) as a case study, the team demonstrates how an integrated platform can transform laboratory observations into clinically relevant insights.

The Thoracic Oncology Database integrates clinical data, database software, research specimens, and institutional collaboration.

Methods

The TOPDP utilizes a relational database structure designed to minimize redundancy and maximize query flexibility. The system is built around four primary tables: Patients (demographics), DNA Specimens (genomics), TMA (proteomics), and Sample Data (linking records to specimens).

To characterize the proteomics of NSCLC, the researchers employed Tissue Microarrays (TMAs). They extracted 1-mm "punches" of tumor and adjacent normal tissue from 105 patients. These specimens were analyzed using Immunohistochemistry (IHC) to stain for 33 different protein biomarkers, which were then scored by pathologists on a semi-quantitative scale (0–3).

The process of creating and analyzing Tissue Microarrays (TMAs) involves taking tumor punches, creating a multi-core slide, and performing immunohistochemical staining.

Heat maps and multivariate Cox regression models were subsequently used to correlate protein expression levels with patient survival outcomes.

Results and Key Insights

The study identified 15 key biomarkers significantly overexpressed in tumor tissue compared to matched normal tissue. Notably, proteins in the Receptor Tyrosine Kinase (RTK) family were among the most frequently overexpressed, reinforcing their potential as targets for drug therapies.

A significant finding involved the localization of proteins. For instance, c-Met showed higher expression in the cytoplasm of tumor cells but was more prevalent in the nucleus or membranes of normal cells, suggesting that protein location within the cell is as critical as its overall abundance.

The most striking clinical correlation involved the Glucocorticoid Receptor (GR). While its expression levels did not differ significantly between tumor and normal tissue, patients whose tumors overexpressed GR had a significantly higher median survival rate (43 months) compared to those with low expression (14 months). Interestingly, protein expression did not vary significantly across different disease stages (I-IV) or histologies, suggesting some universal proteomic signatures in NSCLC.

Discussion and Future Directions

The TOPDP demonstrates the power of "exploratory data mining" by unifying disparate data types. However, the study faces limitations, including a relatively small proteomic sample size (105 patients) compared to the total clinical database (>2,500 patients). Additionally, the use of "adjacent normal" tissue as a control may be imperfect due to potential field effects from the nearby tumor.

Future work focuses on expanding the molecular depth of the entire cohort and transitioning the TOPDP to a web-based platform. This evolution will facilitate multi-institutional collaboration and larger-scale data aggregation, further enhancing the search for actionable targets in thoracic malignancies.

Summary updated

Abstract

Though the database project is still under development, the application of such a database has the potential to enhance our understanding of cancer biology and will help researchers to identify targets to modify the course of thoracic malignancies.
BibTeX
@article{surati2011proteomic,
  author = {Mosmi Surati and Matthew R. Robinson and Suvobroto Nandi and Leonardo Faoro and Carley Demchuk and Cleo E. Rolle and Rajani Kanteti and Benjamin D. Ferguson and Rifat Hasina and Tara C. Gangadhar and April K.S. Salama and Qudsia Arif and Colin Kirchner and Eneida A. Mendonça and Nicholas Campbell and Suwicha Limvorasak and Victoria Villaflor and Thomas A. Hensing and Thomas Krausz and Everett E. Vokes and Aliya N. Husain and Mark K. Ferguson and Theodore Karrison and Ravi Salgia},
  title = {{Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database}},
  journal = {Journal of Clinical Bioinformatics},
  year = {2011},
  doi = {10.1186/2043-9113-1-8},
}
Figure